Pharvaris/$PHVS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Pharvaris
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.
Ticker
$PHVS
Sector
Primary listing
Employees
-
Headquarters
Zug, Switzerland
Website
Pharvaris Metrics
BasicAdvanced
$1.6B
-
-$3.59
-2.81
-
Price and volume
Market cap
$1.6B
Beta
-2.81
52-week high
$26.33
52-week low
$11.51
Average daily volume
196K
Financial strength
Current ratio
8.326
Quick ratio
8.086
Long term debt to equity
0.256
Total debt to equity
0.344
Profitability
EBITDA (TTM)
-192.281
Effective tax rate (TTM)
-1.19%
Management effectiveness
Return on assets (TTM)
-36.84%
Return on equity (TTM)
-65.09%
Valuation
Price to book
6.53
Price to tangible book (TTM)
6.53
Price to free cash flow (TTM)
-7.496
Free cash flow yield (TTM)
-13.34%
Free cash flow per share (TTM)
-2.932
Growth
Earnings per share change (TTM)
30.76%
3-year earnings per share growth (CAGR)
27.11%
What the Analysts think about Pharvaris
Analyst ratings (Buy, Hold, Sell) for Pharvaris stock.
Bulls say / Bears say
Deucrictibant received orphan designation from the European Commission on March 25, 2025, granting 10 years of market exclusivity in the EU and strengthening its commercial outlook (EMA).
The RAPIDe-3 pivotal Phase 3 on-demand study reached target enrollment of approximately 120 participants in March 2025, reinforcing confidence in the program’s execution and timeline (Nasdaq).
The FDA granted TQT study waivers for both extended- and immediate-release formulations of deucrictibant in May 2025, streamlining the development pathway by eliminating dedicated cardiac safety trials (Nasdaq).
2024 net loss reached €134 million, up from €100.9 million in 2023, reflecting mounting operating deficits amid late‐stage development (Nasdaq).
Full‐year 2024 R&D expenses surged to €98.6 million, a 50 percent increase year‐over‐year, underscoring escalating development costs without current revenue support (Nasdaq).
Cash and cash equivalents fell by €110 million year-over-year to €281 million as of December 31, 2024, indicating a high burn rate that may necessitate additional financing before commercialization (Nasdaq).
Data summarised monthly by Lightyear AI. Last updated on 3 Oct 2025.
Pharvaris Financial Performance
Revenues and expenses
Pharvaris Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Pharvaris stock?
Pharvaris (PHVS) has a market cap of $1.6B as of October 14, 2025.
What is the P/E ratio for Pharvaris stock?
The price to earnings (P/E) ratio for Pharvaris (PHVS) stock is 0 as of October 14, 2025.
Does Pharvaris stock pay dividends?
No, Pharvaris (PHVS) stock does not pay dividends to its shareholders as of October 14, 2025.
When is the next Pharvaris dividend payment date?
Pharvaris (PHVS) stock does not pay dividends to its shareholders.
What is the beta indicator for Pharvaris?
Pharvaris (PHVS) has a beta rating of -2.81. This means that it has an inverse relation to market volatility.